Atherosclerosis Drugs Market Size Worth USD 60.97 Billion in 2030 | Emergen Research
The global atherosclerosis drugs market size reached USD 48.40 Billion in 2021 and is expected to register a revenue CAGR of 2.5% during the forecast period, according to latest analysis by Emergen Research. The growing prevalence of atherosclerosis and other cardiovascular diseases is anticipated to boost the demand for atherosclerosis drugs over the forecast period. According to the World Health Organization (WHO), in 2016, around 17.9 million people died from cardiovascular diseases, representing 31% of all global deaths. Of these deaths, 85% were due to heart attacks and strokes.
Rising geriatric population is another key factor expected to fuel the market growth over the forecast period. According to the Population Reference Bureau (PRB), the global population aged 60 years or above is projected to reach 2 billion by 2050 from 962 million in 2017. The growing geriatric population is prone to various chronic diseases such as atherosclerosis, which is anticipated to drive the market growth over the next few years.
The COVID-19 pandemic has had a significant impact on the atherosclerosis drugs market. The outbreak of the pandemic has led to the closure of several manufacturing units and hampered the supply chain across the globe. However, with the gradual easing of lockdown restrictions, the market is expected to witness a positive growth over the forecast period.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/1300
Key players in the market are focused on adopting various strategies such as mergers and acquisitions, new product launches, and expansions to gain a competitive edge in the market. For instance, in October 2020, Pfizer Inc. acquired Prevail Therapeutics Inc., a gene therapy company, with an aim to strengthen its portfolio in rare neurological diseases.
Atherosclerosis drugs is a therapeutic category used for the treatment of atherosclerosis and related cardiovascular diseases such as heart attacks, strokes, and peripheral vascular disease. The drugs are classified into statins, fibrates, niacin, proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9), and others.
Statins are the most commonly used drugs for the treatment of atherosclerosis. They are used to lower the levels of low-density lipoprotein (LDL) cholesterol in the blood and prevent the formation of plaque in arteries.
Fibrates are used to treat high triglyceride levels in the blood and are often used in combination with statins.
Niacin is used to treat high cholesterol and is available in both prescription and over-the-counter (OTC) forms.
PCSK9 inhibitors are a new class of drugs used to lower LDL cholesterol levels. They are typically used in patients who are unable to control their LDL cholesterol levels with statins.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/atherosclerosis-drugs-market
Some Key Highlights From the Report
- Some major companies in the global market report include Sanofi, Hoffmann La-Roche Ltd, Bayer AG, Merck & Co., Inc., Pfizer Inc., Novartis AG, GSK plc, Janssen Global Services, LLC, Amgen Inc., Mylan N.V.
- In terms of drug type, the market is classified into statins, fibrates, niacin, proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9), and others. Statins are expected to hold the largest market share over the forecast period due to their efficacy in lowering LDL cholesterol levels and preventing plaque formation in arteries.
- On the basis of route of administration, the market is divided into oral and injectable. The oral segment is expected to hold the largest market share over the forecast period as oral drugs are more convenient to administer than injectable drugs.
- On the basis of distribution channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are expected to hold the largest market share over the forecast period as they offer a wide range of atherosclerosis drugs.
- The global atherosclerosis drugs market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to hold the largest market share over the forecast period due to the growing prevalence of atherosclerosis and related cardiovascular diseases in the region. According to the American Heart Association (AHA), about 17 million people in the U.S. suffer from atherosclerosis.
- Europe is expected to witness a significant growth over the forecast period due to the growing awareness about the disease and the availability of effective treatments in the region. Asia Pacific is expected to be the fastest-growing market over the forecast period due to the growing prevalence of atherosclerosis and related cardiovascular diseases in the region.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/1300
Emergen Research has segmented global atherosclerosis drugs market on the basis of drug class, medication, distribution channel, and region:
- Drug Class Outlook (Revenue, USD Billion; 2019-2030)
- Statins
- Fibrates
- Vitamins
- Others
- Medication Outlook (Revenue, USD Billion; 2019-2030)
- Cholesterol Lowering Medication
- Beta Blockers
- Calcium Channel Blockers
- Diuretics
- Others
- Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Regional Outlook (Revenue, USD Billion; 2019-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
- North America
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/1300
Explore More Reports Emergen Research:
Polyvinylidene fluoride market
Legal Online Dispute Resolution Market
In silico drug discovery market
Hemodynamic Monitoring Devices Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/industry-report/atherosclerosis-drugs-market
Explore Our Custom Intelligence services | Growth Consulting Services
Latest Published Titles Smart Cities Market | Smart Learning Market
Trending Titles Humanoid Robot Market | Incident Response Market